

1 **Effectiveness of COVID-19 Vaccines at Preventing Emergency Department or Urgent Care Encounters**
2 **and Hospitalizations Among Immunocompromised Adults: An Observational Study of Real-World Data**
3 **Across 10 US States from August-December 2021**

4 Peter J. Embi^{1,2}, Matthew E. Levy³, Palak Patel⁴, Malini B. DeSilva⁵, Manjusha Gaglani⁶, Kristin Dascomb⁷,
5 Margaret M. Dunne³, Nicola P. Klein⁸, Toan C. Ong⁹, Shaun J. Grannis^{2,10}, Karthik Natarajan^{11,12}, Duck-Hye
6 Yang³, Edward Stenehjem⁷, Oussen Zerbo⁸, Charlene McEvoy⁵, Suchitra Rao⁹, Mark G. Thompson⁴,
7 Deepika Konatham⁶, Stephanie A. Irving¹³, Brian E. Dixon^{2,14}, Jungmi Han¹¹, Kristin E. Schrader³, Nancy
8 Grisel⁷, Ned Lewis⁸, Anupam B. Kharbanda¹⁵, Michelle A. Barron⁹, Sue Reynolds⁴, I-Chia Liao⁶, William F.
9 Fadel^{2,14}, Elizabeth A. Rowley³, Julie Arndorfer⁷, Kristin Goddard⁸, Kempapura Murthy⁶, Nimish R. Valvi²,
10 Zachary A. Weber³, Bruce Fireman⁸, Sarah E. Reese³, Sarah W. Ball³, Allison L. Naleway¹³

11 ¹Vanderbilt University Medical Center, Nashville, Tennessee, USA; ²Center for Biomedical Informatics,
12 Regenstrief Institute, Indianapolis, Indiana, USA; ³Westat, Rockville, Maryland, USA; ⁴Centers for
13 Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, USA; ⁵HealthPartners
14 Institute, Minneapolis, Minnesota, USA; ⁶Baylor Scott & White Health, Texas A&M College of Medicine,
15 Temple, Texas, USA; ⁷Division of Infectious Diseases and Clinical Epidemiology, Intermountain
16 Healthcare, Salt Lake City, Utah, USA; ⁸Kaiser Permanente Vaccine Study Center, Kaiser Permanente
17 Northern California Division of Research, Oakland, California, USA; ⁹School of Medicine, University of
18 Colorado Anschutz Medical Campus, Aurora, Colorado, USA; ¹⁰Indiana University School of Medicine,
19 Indianapolis, Indiana, USA; ¹¹Department of Biomedical Informatics, Columbia University Irving Medical
20 Center, New York, New York, USA; ¹²New York Presbyterian Hospital, New York, New York, USA; ¹³
21 Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA; ¹⁴Fairbanks School of
22 Public Health, Indiana University, Indianapolis, Indiana, USA; ¹⁵Children's Minnesota, Minneapolis, MN,
23 USA

24 **Disclaimers:** The findings and conclusions in this report are those of the authors and do not necessarily
25 represent the views of the US Centers for Disease Control and Prevention.

26 **Key Words:** COVID-19, vaccine effectiveness, mRNA vaccines, immunocompromised, hospitalization

27 **Running Title:** COVID-19 Vaccines in Immunocompromised

28 **Key points:** During Delta variant predominance, immunocompromised (IC) adults received moderate
29 protection against COVID-19-associated medical events from three mRNA doses, but IC patients,
30 especially transplant recipients, were less protected than non-IC patients, underscoring the need for
31 additional protection beyond the primary series.

32 **Corresponding author:** Peter J. Embi, MD, MS, FACP, FACMI, FIAHSI, Vanderbilt University Medical
33 Center, 2525 West End Avenue, Suite 1475, Nashville, TN 37203, email: peter.embi@vumc.org, phone:
34 615-936-6867, fax: 615-936-010

35 **Alternate corresponding author:** Matthew E. Levy, PhD, Public Health & Epidemiology Practice, Westat,
36 1600 Research Blvd, Rockville, MD 20850, email: matthewlevy@westat.com, phone: 301-251-1500, fax:
37 301-610-4820

38 **Manuscript Word Count:** 3,476

39 **ABSTRACT**

40 **Background:** Immunocompromised (IC) persons are at increased risk for severe COVID-19 outcomes and
41 are less protected by 1-2 COVID-19 vaccine doses than are immunocompetent (non-IC) persons. We
42 compared vaccine effectiveness (VE) against medically attended COVID-19 of 2-3 mRNA and 1-2 viral-
43 vector vaccine doses between IC and non-IC adults.

44 **Methods:** Using a test-negative design among eight VISION Network sites, VE against laboratory-
45 confirmed COVID-19–associated emergency department (ED) or urgent care (UC) events and
46 hospitalizations from 26 August-25 December 2021 was estimated separately among IC and non-IC
47 adults and among specific IC condition subgroups. Vaccination status was defined using number and
48 timing of doses. VE for each status (versus unvaccinated) was adjusted for age, geography, time, prior
49 positive test result, and local SARS-CoV-2 circulation.

50 **Results:** We analyzed 8,848 ED/UC events and 18,843 hospitalizations among IC patients and 200,071
51 ED/UC events and 70,882 hospitalizations among non-IC patients. Among IC patients, 3-dose mRNA VE
52 against ED/UC (73% [95% CI: 64-80]) and hospitalization (81% [95% CI: 76-86]) was lower than that
53 among non-IC patients (ED/UC: 94% [95% CI: 93-94]; hospitalization: 96% [95% CI: 95-97]). Similar
54 patterns were observed for viral-vector vaccines. Transplant recipients had lower VE than other IC
55 subgroups.

56 **Conclusions:** During B.1.617.2 (Delta) variant predominance, IC adults received moderate protection
57 against COVID-19–associated medical events from three mRNA doses, or one viral-vector dose plus a
58 second dose of any product. However, protection was lower in IC versus non-IC patients, especially
59 among transplant recipients, underscoring the need for additional protection among IC adults.

60 **INTRODUCTION**

61 Immunocompromised (IC) persons, or those with suppressed humoral or cellular immunity
62 resulting from health conditions or medication use, comprise approximately 3% of the U.S. adult
63 population [1, 2]. IC adults are at increased risk for severe COVID-19 outcomes such as hospitalization
64 and death [3-6] and acquire less protection from two COVID-19 mRNA vaccine doses as do
65 immunocompetent (non-IC) persons [7]. Analyses of real-world data have also demonstrated differential
66 vaccine effectiveness (VE) across subgroups of patients with a range of IC conditions [7]. While a third
67 COVID-19 mRNA vaccine dose has been recommended as part of the primary series for IC persons since
68 August 2021 [8], limited evidence exists regarding VE of three mRNA doses for preventing severe
69 outcomes such as COVID-19–associated emergency department (ED) and urgent care (UC) events or
70 hospitalizations among adults with different types of IC conditions [9, 10].

71 The objective of this study was to estimate, using electronic health record (EHR)-derived data
72 during a period of B.1.617.2 (Delta) variant predominance, the relative VE against laboratory-confirmed
73 COVID-19-associated ED/UC events and hospitalization of 3 versus 2 mRNA vaccine doses and 2 versus 1
74 viral-vector vaccine dose(s). Estimates also include absolute VE of each vaccinated group compared with
75 unvaccinated status. VE was calculated separately and compared between IC and non-IC adults and
76 among different subgroups with specific types of IC conditions. Determining the real-world effectiveness
77 of 3 mRNA doses and 2 viral-vector doses will inform recommendations for IC patients. They will also
78 provide a basis for future analyses during periods when other variants predominate and when sufficient
79 data have accrued to examine four- and five-dose regimens among IC patients [8].

80 **METHODS**

81 **Study Setting and Data Source**

82 The VISION Network is a collaboration between the Centers for Disease Control and Prevention
83 (CDC) and eight U.S. health care systems and research centers in 10 states, with integrated medical,
84 laboratory, and vaccination records: Baylor Scott & White Health (Texas), Columbia University Irving
85 Medical Center (New York), HealthPartners Institute (Minnesota, Wisconsin), Intermountain Healthcare
86 (Utah), Kaiser Permanente Northern California, Kaiser Permanente Northwest (Oregon, Washington),
87 Regenstrief Institute (Indiana), and the University of Colorado [7, 11-15].

88 Within the framework of a test-negative design [16-19], encounters among persons admitted to
89 one of 391 ED/UC facilities and persons hospitalized (>24 hours) at one of 261 hospitals were eligible if
90 patients were aged ≥ 18 years with ≥ 1 discharge diagnosis among a previously published list of qualifying
91 COVID-19–like illness (CLI) diagnoses [11]. CLI was defined as a clinical diagnosis (from the International
92 Classification of Diseases [ICD], 9th and 10th Revisions) of acute respiratory illness (e.g., respiratory
93 failure or pneumonia) or signs or symptoms (e.g., cough, fever, dyspnea, vomiting, or diarrhea) that are
94 associated with COVID-19 [20-22]. CLI encounters included ED/UC events and hospitalizations between
95 August 26, 2021 (14 days after the first U.S. recommendation for a third mRNA COVID-19 vaccine dose
96 as part of the primary series for IC individuals [23]) and December 15–25, 2021 (last date during which
97 the Delta variant accounted for >50% of sequenced viruses at each study site [13]). Repeat ED visits and
98 repeat UC clinic visits (within 24 hours) and or hospital readmissions within 30 days post-discharge were
99 combined and analyzed as single medical visits. This study was reviewed and approved by the
100 institutional review board at Westat, Inc.

101 **Measures**

102 IC status was defined by the presence (presumed IC) or absence (presumed non-IC) of ≥ 1
103 discharge diagnosis for immunocompromising conditions, as previously published [7]. Diagnoses across
104 five categories of conditions were derived from previous studies of large hospital-based or

105 administrative databases: 1) solid malignancies, 2) hematologic malignancies, 3) rheumatologic or
106 inflammatory disorders, 4) other intrinsic immune conditions or immunodeficiencies, and 5) organ or
107 stem cell transplants [24-26] (**Supplementary Table 1**). Data on immunosuppressive medications were
108 not available.

109 Vaccination status was documented in EHRs or state or local immunization registries [11] and
110 was defined as of the medical event index, or the date of specimen collection associated with the most
111 recent SARS-CoV-2 test result before the ED/UC event or hospitalization (or, if testing only occurred
112 after admission, the date of admission). Primary analyses included recipients of Moderna (mRNA-1273)
113 and/or Pfizer-BioNTech (BNT162b2) products. Patients were classified as unvaccinated, 2-dose mRNA-
114 vaccinated (≥ 14 days earlier), or 3-dose mRNA-vaccinated (≥ 7 days earlier). Patients with two doses
115 were further subdivided as < 150 and ≥ 150 days earlier. We excluded mRNA vaccine recipients who
116 received 1) only 1 dose, 2) second dose 1–13 days earlier, 3) third dose 1–6 days earlier, or 4) ≥ 4 doses.
117 Secondary analyses included Janssen (Johnson & Johnson [Ad26.COV2]) vaccine recipients, with patients
118 classified as 1-dose Janssen-vaccinated (≥ 14 earlier) or 2-dose vaccinated (≥ 7 days earlier). Due to
119 sample size constraints, any product was used to define second dose (i.e., mRNA or Janssen). Among
120 Janssen recipients, we excluded those who received 1) first dose 1–13 days earlier, 2) second dose (any
121 product) 1–6 days earlier, or 3) ≥ 3 doses.

122 SARS-CoV-2 infection was confirmed by molecular assays (e.g., real-time reverse-transcriptase–
123 polymerase-chain-reaction [RT-PCR] assays) obtained within 14 days before to < 72 hours after an ED/UC
124 clinic visit or hospital admission. We only included events with an available SARS-CoV-2 molecular test
125 result during this window. To minimize confounding related to recent infection, patients with a positive
126 SARS-CoV-2 result 15–89 days earlier were excluded. Demographics and underlying medical conditions
127 (defined by ICD codes assigned at medical event) were extracted from EHRs.

128 **Statistical Analysis**

129 A test-negative design was used to assess VE with respect to an ED/UC event or hospitalization
130 associated with laboratory-confirmed SARS-CoV-2 infection and CLI. VE was estimated by comparing
131 odds of a positive SARS-CoV-2 test result between vaccinated and unvaccinated patients using
132 multivariable logistic regression models [7, 11, 13]. VE was adjusted for age (spline), geographic region,
133 calendar time (spline), prior documented positive SARS-CoV-2 test result (none, 90–364 days ago, ≥365
134 days ago), and local SARS-CoV-2 circulation (7-day moving average of percentage of RT-PCR tests that
135 were SARS-CoV-2–positive within the medical facility’s geographic region; spline). VE was also weighted
136 for patients’ inverse propensity to be vaccinated (if vaccinated) or unvaccinated (if not vaccinated).
137 Generalized boosted regression trees were used to estimate the propensity to be vaccinated based on
138 sociodemographics, underlying medical conditions, known prior SARS-CoV-2 infection (pre-vaccination,
139 if vaccinated), and facility characteristics. Separate weights were calculated for each VE model and were
140 truncated at the 99th percentile of the distribution of weights. Any covariates with an absolute
141 standardized mean or proportion difference (SMD) ≥0.20 after weighting were also included in the
142 model for the respective VE estimate(s) to minimize residual confounding.

143 VE estimates were stratified by IC status, vaccine product received, age group (18–64, ≥65
144 years), and race/ethnicity (non-Hispanic white, non-Hispanic Black, Hispanic). Among IC patients, VE was
145 also calculated separately among five mutually exclusive subgroups of patients with each type of
146 immunocompromising diagnosis (patients with multiple types were excluded) and separately among
147 recipients and non-recipients of organ/stem cell transplants (no patients excluded). To directly compare
148 the 3-dose versus 2-dose mRNA vaccine series, relative VE was calculated using a similar methodology
149 with 2 doses serving as the referent group. Effect modification by IC status (IC vs. non-IC) and type of IC
150 condition (transplant recipient vs. non-transplant recipient) was assessed using interaction terms with
151 vaccination status in regression models. To evaluate mRNA product differences, a contrast was used to

152 test differences in regression coefficients between Moderna and Pfizer-BioNTech. P-values <0.05 were
153 considered statistically significant. Analyses were performed using SAS version 9.4 (SAS Institute) or R
154 software, version 4.1.2 (R Foundation for Statistical Computing).

155 **RESULTS**

156 **Descriptive Characteristics**

157 A total of 208,919 ED/UC medical events and 89,725 hospitalizations were identified during
158 August 26–December 25, 2021, among adults with CLI and SARS-CoV-2 testing who were either
159 unvaccinated or had received 2-3 mRNA vaccine doses. Characteristics of non-IC and IC patients overall
160 and by vaccination status are provided in **Table 1** for ED/UC events and **Table 2** for hospitalizations. The
161 proportions of all ED/UC events and hospitalizations that were among IC persons were 4% and 21%,
162 respectively. Median age was 47 years (interquartile range [IQR]: 31–66) and 65 years (IQR: 48–77)
163 among non-IC patients in ED/UC and hospital settings, respectively, and 66 years (IQR: 54–75) and 68
164 years (IQR: 58–77) among IC patients in those settings (data not shown). Overall, proportions of ED/UC
165 events among non-Hispanic Black and Hispanic patients were 9% and 15%, respectively, and 11% and
166 12% for hospitalizations. Overall, a smaller proportion of ED/UC (19%) than hospitalized (64%) patients
167 had a discharge diagnosis for a chronic respiratory condition. Proportions of ED/UC events and
168 hospitalizations among patients with a historical positive SARS-CoV-2 test result ≥ 90 days earlier was 6–
169 7%. There were differences by network site, age, and race/ethnicity between 2-/3-doses mRNA-
170 vaccinated and unvaccinated patients. The application of inverse propensity-to-be-vaccinated weighting
171 reduced differences between vaccinated and unvaccinated patients with respect to these and other
172 factors (**Supplementary Tables 2-3**).

173 Among 8,848 ED/UC events and 18,843 hospitalizations for IC patients, 36% and 42%,
174 respectively, had a discharge diagnosis for solid malignancy, compared with diagnoses for hematologic

175 malignancy (11%/13%), rheumatologic/inflammatory disorder (27%/25%), another intrinsic immune
176 condition or underlying immunodeficiency (34%/35%), and organ/stem cell transplant (9%/8%) (data not
177 shown). The majority of ED/UC visits (84%) and hospitalizations (79%) had only one of these five types,
178 whereas 14% and 18%, respectively, had exactly two, 1%/2% had three, and <0.1%/0.3% had four or
179 five.

180 In both settings, a smaller proportion of non-IC patients were vaccinated with two (45% in both
181 settings) or three (8%/9%) mRNA vaccine doses compared with IC patients (two doses: 48%/51%; three
182 doses: 16%/18%) (**Tables 1-2**). Overall, 38% and 41% of vaccinated non-IC patients in ED/UC and hospital
183 settings, received the Moderna vaccine, compared with 61%/58% with the Pfizer-BioNTech vaccine and
184 1%/1% with a combination of both products. Among vaccinated IC patients, 38% and 40% in ED/UC and
185 hospital settings received the Moderna vaccine, compared with 61%/59% with the Pfizer-BioNTech
186 vaccine and 1%/1% with a combination.

187 In ED/UC settings, the median time since 2-dose mRNA-vaccinated patients' second dose was
188 189 days among non-IC patients (IQR: 146–225) and 196 days among IC patients (IQR: 160–230); median
189 durations in hospitals were 199 days (IQR: 161–233) and 198 days (IQR: 163–231), respectively (data not
190 shown). In ED/UC settings, the median time since 3-dose mRNA-vaccinated patients' third dose was 35
191 days among non-IC patients (IQR: 17–49) and 45 days among IC patients (IQR: 26–72); median time in
192 hospitals was 34 days (IQR: 19–54) among non-IC and 43 days (IQR: 24–66) among IC patients.
193 Distributions were similar by mRNA vaccine product.

194 **mRNA COVID-19 VE by Immunocompromised Status**

195 Among 200,071 ED/UC events for non-IC patients, 21% had laboratory-confirmed SARS-CoV-2
196 infection (35% infected among unvaccinated; 10% among 2-dose vaccinated; 3% among 3-dose
197 vaccinated), compared with 13% among 8,848 ED/UC events for IC patients (21% infected among

198 unvaccinated; 9% among 2-dose vaccinated; 5% among 3-dose vaccinated). Among IC adults, 2-dose
199 mRNA VE was 67% (95% confidence interval [CI]: 62–72) and 3-dose mRNA VE was 73% (95% CI: 64–80)
200 against SARS-CoV-2 infection at an ED/UC event, compared with 81% (95% CI: 81–82) and 94% (95% CI:
201 93–94) among non-IC adults (**Table 3**). VE against ED/UC events for 2 and 3 doses was significantly lower
202 among IC versus non-IC patients (tests of interaction, both $p < 0.05$).

203 Among 70,882 hospitalizations for non-IC patients, 22% had SARS-CoV-2 infection (41% infected
204 among unvaccinated; 8% among 2-dose vaccinated; 2% among 3-dose vaccinated), compared with 11%
205 among 18,843 hospitalizations for IC patients (22% infected among unvaccinated; 7% among 2-dose
206 vaccinated; 3% among 3-dose vaccinated). Among IC adults, 2-dose mRNA VE was 72% (95% CI: 69-75)
207 and 3-dose mRNA VE was 81% (95% CI: 76-86) against SARS-CoV-2 infection at hospitalization,
208 compared with 87% (95% CI: 86-87) and 96% (95% CI: 95-97), respectively, among non-IC adults. VE
209 against hospitalization for 2 and 3 doses was significantly lower among IC versus non-IC patients (tests of
210 interaction, both $p < 0.05$). VE point estimates were similarly lower among IC versus non-IC patients in
211 analyses stratified by age group and race/ethnicity (**Supplementary Tables 4-5**).

212 In ED/UC and hospital settings, point estimates for 2-dose mRNA VE were lower among patients
213 with ≥ 150 versus < 150 days elapsed since second dose (**Table 3**). Further, among IC patients in both
214 settings, 2-dose VE was higher for Moderna than Pfizer-BioNTech products (both $p < 0.05$). Similarly,
215 among IC patients, 3-dose VE was higher for Moderna than Pfizer-BioNTech products in hospital settings
216 ($p < 0.05$), but no significant difference was observed in ED/UC settings ($p = 0.61$). In relative VE analyses
217 among IC patients, three mRNA doses were significantly more effective than two mRNA doses in ED/UC
218 settings (44%; 95% CI: 24–58) and hospital settings (48%; 95% CI: 34–59); results were similar for both
219 Moderna and Pfizer-BioNTech products (**Table 4**).

220 **mRNA COVID-19 VE by Type of Immunocompromising Condition**

221 Among patients with only one type of immunocompromising condition, VE against COVID-19–
222 associated ED/UC events after 2-dose mRNA vaccination for IC patient groups ranged from 11% (95% CI:
223 -102-61) among organ/stem cell transplant recipients to 82% (95% CI: 66-90) among patients with
224 hematologic malignancy. 3-dose VE ranged from 50% (95% CI: -36-81) among patients with hematologic
225 malignancy to 87% (95% CI: 70-95) among patients with solid malignancy (**Table 5**). VE against COVID-
226 19–associated hospitalizations of patients with 2-dose mRNA vaccination ranged from 73% (95% CI: 49-
227 86) among organ/stem cell transplant recipients to 83% (95% CI: 77-87) among patients with another
228 intrinsic immune condition or underlying immunodeficiency. VE of 3-dose mRNA vaccination ranged
229 from 39% (95% CI: -69-78) among organ/stem cell transplant recipients to 92% (95% CI: 84-96) among
230 patients with solid malignancy.

231 VE of 2-dose and 3-dose mRNA vaccination (each versus unvaccinated status) was lower among
232 transplant recipients than among non-transplant recipients with other immunocompromising
233 condition(s) in ED/UC and inpatient settings (tests of interaction between organ/stem cell transplant
234 status and vaccination status, all $p < 0.05$) (**Table 5**). Among transplant recipients, two or three doses of
235 Moderna were more effective than two or three doses of Pfizer-BioNTech against COVID-19
236 hospitalization (both $p < 0.05$), but no product difference was detected with respect to VE against COVID-
237 19 ED/UC events (both $p > 0.25$).

238 **Janssen (Johnson & Johnson) COVID-19 VE**

239 A total of 10,329 ED/UC events (5% IC) and 4,202 hospitalizations (23% IC) were among Janssen
240 vaccine recipients. Characteristics of non-IC and IC Janssen vaccine recipients in ED/UC and hospital
241 settings are provided in **Supplementary Tables 6-7**. Among Janssen vaccine recipients, 7% of non-IC
242 patients and 6% of IC patients in ED/UC settings, and 6% and 5%, respectively, in hospital settings, had
243 received a second dose (any product). Among those who received a second dose, 67% and 63% of non-

244 IC patients in ED/UC and hospital settings, respectively, and 77% and 69% of IC patients in those settings
245 had a heterologous dosing pattern (i.e., mRNA product as second dose).

246 In ED/UC settings, median duration since 1-dose Janssen-vaccinated patients' first dose was 182
247 days among non-IC patients (IQR: 139–219) and 190 days among IC patients (IQR: 148–227); median
248 durations in hospitals were 179 days (IQR: 134–215) and 185 days (IQR: 147–218), respectively. In
249 ED/UC settings, median duration since 2-dose Janssen-vaccinated patients' second dose (any product)
250 was 26 days among non-IC patients (IQR: 16–40) and 20 days among IC patients (IQR: 12–37); median
251 durations in hospitals were 26 days (IQR: 15–38) and 29 days (IQR: 17–40), respectively.

252 Among IC adults, VE of one Janssen dose was 7% (95% CI: -26–31) and VE of two doses (any
253 product for second dose) was 71% (95% CI: 6–91) against COVID-19 ED/UC events, compared with 64%
254 (95% CI: 61–66) and 90% (95% CI: 86–93), respectively, among non-IC adults (**see Supplementary Table**
255 **8**). VE for 1 Janssen dose was significantly lower among IC versus non-IC patients (test of interaction,
256 $p < 0.05$); there was no statistical difference for 2 doses. Among IC adults, VE of one Janssen dose was
257 45% (CI: 29–57) and VE of two doses was 70% (95% CI: 25–88) against COVID-19 hospitalization,
258 compared with 72% (95% CI: 69–76) and 93% (95% CI: 86–96), respectively, among non-IC adults (tests
259 of interaction between IC status and vaccination status, $p < 0.05$ for 1 dose and 2 doses).

260 **DISCUSSION**

261 In a multistate analysis of real-world EHR-derived data from nearly 209,000 ED/UC events and
262 90,000 hospitalizations during Delta variant predominance, 3 doses among mRNA COVID-19 vaccine
263 recipients and 2 doses among viral-vector vaccine recipients (any product for second dose) were more
264 effective at preventing laboratory-confirmed COVID-19 medical events in IC and non-IC patients
265 compared with receipt of 2 mRNA vaccine doses, one viral-vector vaccine dose, or being unvaccinated.
266 While this additional primary series dose offers further protection to IC patients, VE estimates among IC

267 patients who received 3 doses of mRNA vaccines or 2 doses of a viral-vector containing series were
268 significantly lower than VE among non-IC patients. These findings indicate that, as a group, IC patients
269 receive less protection from vaccination, compared with the protection received by non-IC patients.
270 These findings are consistent with other studies suggesting that certain IC populations experience
271 attenuated immune responses to COVID-19 vaccines and that VE is reduced among IC patients overall
272 [3, 27]. To our knowledge, this study is among the first to report different estimates for 3-dose mRNA VE
273 across groups with different IC conditions, with point estimates ranging from 50–87% (ED/UC) and 39–
274 92% (hospital). Specifically, and consistent with our previous study of 2-dose vaccination, VE was again
275 found to be especially low for patients with organ or stem cell transplants, confirming that this
276 population is at particular risk of lower protection from severe COVID-19 outcomes even when
277 vaccinated [7].

278 Our results highlight the need for extra protection against COVID-19 among IC adults. Therefore,
279 they support the recommendation that all eligible persons should receive multiple vaccine doses, and
280 that IC persons should receive more than non-IC persons, to enhance protection against severe COVID-
281 19. They also add to evidence suggesting that, compared with non-IC persons, IC populations may have
282 a greater need for additional measures (masking, physical distancing, pre-exposure prophylaxis) to
283 prevent COVID-19.

284 To our knowledge, this study is also among the first to show a statistically significant difference
285 in VE between mRNA products among IC patients. Our network’s previous study demonstrated a trend
286 toward a greater protective effect of the Moderna versus Pfizer-BioNTech mRNA vaccine, and this study
287 provides more rigorous statistical evidence of this difference [7]. Therefore, while this is an
288 observational study with some inherent limitations noted below, and while either mRNA vaccine
289 provides good VE for IC patients, this finding is notable and deserving of further study and

290 consideration. It should also be noted that we did not have sufficient power to directly compare relative
291 VE between viral-vector and mRNA vaccine products.

292 This study has several strengths, including its large and diverse sample, but it is also subject to
293 several limitations. First, the use of selected discharge diagnoses as surrogates for presumed IC status
294 and the absence of medication and other relevant data might have led to classification of persons as IC
295 who were not; the opposite is also possible but less likely. Second, despite each network partner's data
296 linkage with state or local immunization registries, misclassification of vaccination status is possible.
297 Third, although inverse weights balanced unvaccinated and vaccinated patients on sociodemographic
298 and health characteristics, and further adjustments were made, unmeasured and residual confounding
299 (e.g., mask-wearing, waning immunity) in this observational study might have influenced estimates. For
300 example, prior SARS-CoV-2 infection could only be controlled for if it was documented in the EHR.
301 Fourth, this study was limited to the period of Delta variant predominance and findings may differ
302 during the subsequent period of Omicron variant predominance, a matter that will be the focus of
303 future analyses. Finally, although additional mRNA doses are currently recommended for IC patients,
304 current data availability did not yet allow for such analyses, and will also be the focus of future studies.

305 This study has implications for public health and clinical practice. While further analyses should
306 evaluate the effectiveness of four mRNA vaccine doses, patients will benefit from receiving booster
307 COVID-19 vaccine doses. Consistent with current CDC recommendations, booster doses confer greater
308 protection than the primary series alone [8]. However, this study also reinforces the reality that
309 vaccinated IC patients remain less protected than vaccinated non-IC patients and may benefit more
310 from additional precautions, including the use of nonpharmaceutical prevention strategies such as
311 mask-wearing to prevent SARS-CoV-2 infection. Also, if infected with SARS-CoV-2, IC patients would
312 benefit from being monitored closely and considered early for proven therapies that might prevent
313 progression to severe illness. Additional studies are needed to determine the degree of VE improvement

314 conferred by additional COVID-19 vaccine doses in IC populations, evaluate whether different
315 approaches to vaccine administration might improve VE (e.g., dosage timing, temporarily withholding
316 immunosuppressants), and further evaluate VE differences between vaccines products.

317

318 **Funding:** The VISION Network is supported by the Centers for Disease Control and Prevention (CDC)
319 [contract 75D30120C07986 to Westat, contract 75D30120C07765 to Kaiser Foundation Hospitals]. The
320 CDC was involved in the design and conduct of the study; collection, management, analysis, and
321 interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit
322 the manuscript for publication. CDC controlled publication decisions.

323
324 **Conflicts of Interest:** All authors have completed and submitted the International Committee of Medical
325 Journal Editors form for disclosure of potential conflicts of interest. Nicola P. Klein reports institutional
326 support from Pfizer for COVID-19 vaccine clinical trials. Charlene McEvoy reports institutional support
327 from AstraZeneca for an AZD1222 COVID-19 vaccine trial. Suchitra Rao reports grant support from
328 GlaxoSmithKline and Biofire Diagnostics. Dr. Brian Dixon reports past consulting fees from Merck & Co.
329 for serving on an advisory panel for HPV vaccination. Manjusha Gaglani reports past support from the
330 CDC for the IVY-3 vaccine research. Kempapura Murthy reports past support from the CDC HAIVEN –
331 Hospitalized Adult Influenza Vaccine Effectiveness Network. All other authors report no disclosures
332 relevant to the current manuscript.

333
334 **Acknowledgements:** We would like to acknowledge the contributions of the VISION Network beyond
335 the authors listed; Baylor Scott & White Health: Deborah Hendricks, Jason Ettlinger, Joel Blais, Elisa
336 Priest, Michael Smith, Spencer Rose, Natalie Settele, Jennifer Thomas, Muralidhar Jatla, Madhava
337 Beeram, Alejandro Arroliga; CDC: Catherine H. Bozio, Jill Ferdinands, Eric P. Griggs, Rachael M. Porter,
338 Lenee Blanton, Andrea Steffens, Natalie Olson, Jeremiah Williams, Monica Dickerson, Meredith
339 McMorrow, Stephanie J. Schrag, Jennifer R. Verani, Mehret Wondimu; Center for Health Research,
340 Kaiser Permanente Northwest: Padma Dandamudi, Bradley Crane; HealthPartners: Gabriela Vazquez-
341 Benitez, Inih Essien, Sunita Thapa, Sheryl Kane; School of Medicine, University of Colorado Anschutz

342 Medical Campus: Health Data Compass, David Mayer, Bryant Doyle, Briana Kille, Catia Chavez;
343 Regenstrief Institute: Ashley Wiensch, Amy Hancock; Westat: Maria Demarco, Salome Kiduko, Carly
344 Hallowell, Magdalene Kish, Lemlem Mehari, Yan Zhuang, Alex Hughes, Kristen Butterfield, Jack Davis,
345 Patrick Mitchell, Victoria Lazariu, Weijia Ren, Akintunde Akinseye.

346

347 **Patient Consent Statement:**

348 This study was reviewed and approved by the institutional review board at Westat, Inc. This electronic
349 health record-based study does not include factors necessitating patient consent.

References

1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; 584(7821):430-6.
2. Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. *JAMA* 2016; 316(23):2547.
3. Deepak P, Kim W, Paley MA, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. *Ann Intern Med* 2021; 174(11):1572-85.
4. Negahdaripour M, Shafiekhani M, Moezzi SMI, et al. Administration of COVID-19 vaccines in immunocompromised patients. *Int Immunopharmacol* 2021; 99:108021.
5. Di Fusco M, Lin J, Vaghela S, et al. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. *Expert Rev Vaccines*.2022; 21(4):435-51.
6. Haidar G, Agha M, Bilderback A, et al. Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study. *Clin Infect Dis* 2022; 75(1):e630-e644.
7. Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults — nine states, January–September 2021. *MMWR Morb Mortal Wkly Rep* 2021; 70(44):1553-9.
8. Centers for Disease Control and Prevention. COVID-19 vaccines for moderately or severely immunocompromised people 2022 [Available from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html#:~:text=decreased%20over%20time.-,People%20ages%2012%20years%20and%20older%20who%20are%20moderately%20or,when%20eligible%2C%201%20booster%20dose>].

9. Tenforde MW, Patel MM, Gaglani M, et al. Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults - United States, August-December 2021. *MMWR Morb Mortal Wkly Rep* 2022; 71(4):118-24.
10. Kwon JH, Tenforde MW, Gaglani M, et al. mRNA vaccine effectiveness against COVID-19 hospitalization among solid organ transplant recipients. *J Infect Dis* 2022; 226(5):797-807.
11. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. *N Engl J Med* 2021; 385(15):1355-71.
12. Grannis SJ, Rowley EA, Ong TC, et al. Interim estimates of COVID-19 vaccine effectiveness against COVID-19–associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance — nine states, June–August 2021. *MMWR Morb Mortal Wkly Rep* 2021; 70(37):1291-3.
13. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. *MMWR Morb Mortal Wkly Rep* 2022; 71(4):139-45.
14. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. *MMWR Morb Mortal Wkly Rep* 2022; 71(7):255-63.
15. Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among non-immunocompromised children and adolescents aged

- 5-17 Years - VISION Network, 10 states, April 2021-January 2022. *MMWR Morb Mortal Wkly Rep* 2022; 71(9):352-8.
16. Dean NE, Hogan JW, Schnitzer ME. COVID-19 vaccine effectiveness and the test-negative design. *N Engl J Med* 2021; 385(15):1431-3.
17. Vandembroucke JP, Pearce N. Test-negative designs: differences and commonalities with other case-control studies with "other patient" controls. *Epidemiology* 2019; 30(6):838-44.
18. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical basis of the test-negative study design for assessment of Influenza vaccine effectiveness. *Am J Epidemiol* 2016; 184(5):345-53.
19. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine* 2013; 31(17):2165-8.
20. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus disease 2019 - COVID-NET, 14 states, March 1-30, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69(15):458-64.
21. Kim L, Garg S, O'Halloran A, et al. Risk Factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). *Clin Infect Dis* 2021; 72(9):e206-e14.
22. Cates J, Lucero-Obusan C, Dahl RM, et al. Risk for in-hospital complications associated with COVID-19 and Influenza - veterans health administration, United States, October 1, 2018-May 31, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69(42):1528-34.
23. U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals 2021 [Available from: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised>].

24. Greenberg JA, Hohmann SF, Hall JB, et al. Validation of a method to identify immunocompromised patients with severe sepsis in administrative databases. *Ann Am Thorac Soc* 2016; 13(2):253-8.
25. Hughes K, Middleton DB, Nowalk MP, et al. Effectiveness of influenza vaccine for preventing laboratory-confirmed Influenza hospitalizations in immunocompromised adults. *Clin Infect Dis* 2021; 73(11):e4353-e60.
26. Patel M, Chen J, Kim S, et al. Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States. *Emer Infect Dis* 2020; 26(8):1720-30.
27. Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 messenger RNA for preventing COVID-19 hospitalizations in the United States. *Clin Infect Dis* 2022; 74(9):1515-1524.

Table 1. Characteristics of emergency department (ED) and urgent care (UC) events among non-immunocompromised (non-IC) and immunocompromised (IC) adults with COVID-19–like illness, by mRNA COVID-19 vaccination status, VISION Network, 10 states, August–December 2021 (n=208,919).

Characteristic	Non-immunocompromised adults ^a					Immunocompromised adults ^a				
	Total	By mRNA COVID-19 vaccination status ^b			SMD ^c	Total	By mRNA COVID-19 vaccination status ^b			SMD ^c
		Unvacc.	2 doses	3 doses			Unvacc.	2 doses	3 doses	
n (col %)	n (row %)	n (row %)	n (row %)		n (col %)	n (row %)	n (row %)	n (row %)		
All ED and UC encounters	200071 (100)	94113 (47)	89546 (45)	16412 (8)	–	8848 (100)	3198 (36)	4223 (48)	1427 (16)	–
Site					0.66					0.54
Baylor Scott & White Health	27323 (14)	16210 (59)	9846 (36)	1267 (5)		3572 (40)	1526 (43)	1632 (46)	414 (12)	
Columbia University ^d	3665 (2)	2029 (55)	1525 (42)	111 (3)		212 (2)	69 (33)	123 (58)	20 (9)	
HealthPartners ^d	5285 (3)	1509 (29)	3437 (65)	339 (6)		120 (1)	19 (16)	80 (67)	21 (18)	
Intermountain Healthcare	53189 (27)	22711 (43)	25986 (49)	4492 (8)		2313 (26)	859 (37)	1087 (47)	367 (16)	
Kaiser Permanente Northern California	34974 (17)	8963 (26)	20718 (59)	5293 (15)		928 (10)	120 (13)	513 (55)	295 (32)	
Kaiser Permanente Northwest	15670 (8)	5917 (38)	8007 (51)	1746 (11)		1026 (12)	286 (28)	514 (50)	226 (22)	

Regenstrief Institute	38806 (19)	25067 (65)	11890 (31)	1849 (5)	571 (6)	287 (50)	222 (39)	62 (11)
University of Colorado	21159 (11)	11707 (55)	8137 (38)	1315 (6)	106 (1)	32 (30)	52 (49)	22 (21)
Age group, years					0.80			0.53
18-49	106660 (53)	61986 (58)	41050 (38)	3624 (3)	1701 (19)	934 (55)	608 (36)	159 (9)
50-64	40262 (20)	17754 (44)	19581 (49)	2927 (7)	2380 (27)	969 (41)	1102 (46)	309 (13)
65-74	25165 (13)	7855 (31)	13031 (52)	4279 (17)	2492 (28)	761 (31)	1247 (50)	484 (19)
75-84	18501 (9)	4425 (24)	10308 (56)	3768 (20)	1681 (19)	391 (23)	929 (55)	361 (21)
≥85	9483 (5)	2093 (22)	5576 (59)	1814 (19)	594 (7)	143 (24)	337 (57)	114 (19)
Sex					0.07			0.07
Male	80429 (40)	39953 (50)	33810 (42)	6666 (8)	4018 (45)	1482 (37)	1826 (45)	710 (18)
Female	119642 (60)	54160 (45)	55736 (47)	9746 (8)	4830 (55)	1716 (36)	2397 (50)	717 (15)
Race/ethnicity					0.32			0.25
White, non-Hispanic	128031 (64)	57491 (45)	58706 (46)	11834 (9)	5957 (67)	2045 (34)	2871 (48)	1041 (17)
Black, non-Hispanic	18222 (9)	10883 (60)	6526 (36)	813 (4)	1019 (12)	463 (45)	452 (44)	104 (10)
Hispanic	29598 (15)	14865 (50)	13101 (44)	1632 (6)	1161 (13)	456 (39)	551 (47)	154 (13)
Other, non-Hispanic ^c	11485 (6)	3578 (31)	6520 (57)	1387 (12)	497 (6)	134 (27)	253 (51)	110 (22)
Unknown	12735 (6)	7296 (57)	4693 (37)	746 (6)	214 (2)	100 (47)	96 (45)	18 (8)
Chronic respiratory condition^f					0.07			0.09
Yes	35092 (18)	15629 (45)	16041 (46)	3422 (10)	4244 (48)	1595 (38)	2029 (48)	620 (15)

No	164979 (82)	78484 (48)	73505 (45)	12990 (8)		4604 (52)	1603 (35)	2194 (48)	807 (18)
Vaccine product^g					–				–
Moderna only	40122 (38)	–	35236 (88)	4886 (12)		2150 (38)	–	1698 (79)	452 (21)
Pfizer-BioNTech only	64736 (61)	–	54121 (84)	10615 (16)		3428 (61)	–	2509 (73)	919 (27)
Combination of mRNA products	1100 (1)	–	189 (17)	911 (83)		72 (1)	–	16 (22)	56 (78)

Abbreviations: Col, column; ED, emergency department; SMD, standardized mean or proportion difference; UC, urgent care; Unvacc., unvaccinated.

^a Immunocompromised status at medical events was defined by the presence (presumed immunocompromised) or absence (presumed non-immunocompromised) of at least one discharge code from the International Classification of Diseases, 9th and 10th Revisions, for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.

^b Vaccination status was categorized based on number and type of vaccine dose(s) received before the medical event index date. Unvaccinated patients had not received any COVID-19 vaccine doses. Patients who had received two mRNA vaccine doses were included in the ‘2 doses’ category if their second dose was ≥ 14 days earlier. Patients who had received three mRNA vaccine doses were included in the ‘3 doses’ category if their third dose was ≥ 7 days earlier. Recipients of the Janssen vaccine were excluded from this table.

^c An absolute SMD ≥ 0.20 indicates a non-negligible difference in variable distributions between ED/UC events for vaccinated versus unvaccinated patients. The SMD was calculated as the average of the absolute value of the SMD for vaccinated with 2 doses versus unvaccinated and the absolute value of the SMD for vaccinated with 3 doses versus unvaccinated. All SMDs are reported as the absolute SMD.

^d ED data at Columbia University Irving Medical Center and HealthPartners exclude encounters that were transferred to an inpatient setting.

^e Other race includes Asian, Native Hawaiian, or other Pacific islander, American Indian or Alaska Native, other not listed, and multiple races.

^f Chronic respiratory condition at discharge was defined as the presence of discharge codes from the International Classification of Diseases, 9th and 10th Revisions, for asthma, chronic obstructive pulmonary disease, or other lung disease.

^g Among vaccinated patients.

Table 2. Characteristics of hospitalizations among non-immunocompromised and immunocompromised adults with COVID-19–like illness, by mRNA COVID-19 vaccination status, VISION Network, 10 states, August–December 2021 (n=89,725).

Characteristic	Non-immunocompromised adults ^a					Immunocompromised adults ^a				
	Total	By mRNA COVID-19 vaccination status ^b			SMD ^c	Total	By mRNA COVID-19 vaccination status ^b			SMD ^c
		Unvacc.	2 doses	3 doses			Unvacc.	2 doses	3 doses	
	n (col %)	n (row %)	n (row %)	n (row %)	n (col %)	n (row %)	n (row %)	n (row %)		
All hospitalizations	70882 (100)	32406 (46)	31891 (45)	6585 (9)	–	18843 (100)	5832 (31)	9635 (51)	3376 (18)	–
Site					0.60					0.73
Baylor Scott & White Health	12063 (17)	6390 (53)	4978 (41)	695 (6)		3583 (19)	1501 (42)	1684 (47)	398 (11)	
Columbia University	2307 (3)	1034 (45)	1156 (50)	117 (5)		880 (5)	267 (30)	486 (55)	127 (14)	
HealthPartners	862 (1)	224 (26)	584 (68)	54 (6)		309 (2)	39 (13)	234 (76)	36 (12)	
Intermountain Healthcare	5980 (8)	2953 (49)	2482 (42)	545 (9)		1328 (7)	486 (37)	620 (47)	222 (17)	
Kaiser Permanente Northern California	16254 (23)	3944 (24)	9676 (60)	2634 (16)		5507 (29)	718 (13)	3156 (57)	1633 (30)	
Kaiser Permanente Northwest	3367 (5)	1438 (43)	1554 (46)	375 (11)		925 (5)	289 (31)	485 (52)	151 (16)	
Regenstrief Institute	22284 (31)	12356 (55)	8361 (38)	1567 (7)		3440 (18)	1474 (43)	1608 (47)	358 (10)	
University of Colorado	7765 (11)	4067 (52)	3100 (40)	598 (8)		2871 (15)	1058 (37)	1362 (47)	451 (16)	
Age group, years					0.77					0.61
18-49	18455 (26)	12093 (66)	5729 (31)	633 (3)		2738 (15)	1427 (52)	1057 (39)	254 (9)	
50-64	15896 (22)	8528 (54)	6567 (41)	801 (5)		4782 (25)	1863 (39)	2332 (49)	587 (12)	

65-74	14949 (21)	5640 (38)	7521 (50)	1788 (12)	5416 (29)	1428 (26)	2881 (53)	1107 (20)
75-84	13333 (19)	3940 (30)	7364 (55)	2029 (15)	4202 (22)	817 (19)	2344 (56)	1041 (25)
≥85	8249 (12)	2205 (27)	4710 (57)	1334 (16)	1705 (9)	297 (17)	1021 (60)	387 (23)
Sex					0.04			0.02
Male	31468 (44)	14883 (47)	13598 (43)	2987 (9)	8879 (47)	2720 (31)	4516 (51)	1643 (19)
Female	39414 (56)	17523 (44)	18293 (46)	3598 (9)	9964 (53)	3112 (31)	5119 (51)	1733 (17)
Race/ethnicity					0.32			0.27
White, non-Hispanic	45577 (64)	19882 (44)	20903 (46)	4792 (11)	12481 (66)	3737 (30)	6370 (51)	2374 (19)
Black, non-Hispanic	7944 (11)	4394 (55)	3137 (39)	413 (5)	2018 (11)	760 (38)	1013 (50)	245 (12)
Hispanic	8737 (12)	4407 (50)	3818 (44)	512 (6)	2439 (13)	800 (33)	1252 (51)	387 (16)
Other, non-Hispanic ^d	4161 (6)	1225 (29)	2367 (57)	569 (14)	1304 (7)	250 (19)	742 (57)	312 (24)
Unknown	4463 (6)	2498 (56)	1666 (37)	299 (7)	601 (3)	285 (47)	258 (43)	58 (10)
Chronic respiratory condition^e					0.08			0.08
Yes	44803 (63)	20004 (45)	20342 (45)	4457 (10)	12677 (67)	3793 (30)	6549 (52)	2335 (18)
No	26079 (37)	12402 (48)	11549 (44)	2128 (8)	6166 (33)	2039 (33)	3086 (50)	1041 (17)
ICU admission					0.08			0.16
Admitted to ICU	11435 (16)	5697 (50)	4802 (42)	936 (8)	3967 (21)	1451 (37)	1948 (49)	568 (14)
Not admitted to ICU	59447 (84)	26709 (45)	27089 (46)	5649 (10)	14876 (79)	4381 (29)	7687 (52)	2808 (19)
Vaccine product^f					–			–

Moderna only	15646 (41)	–	13685 (87)	1961 (13)	5155 (40)	–	4005 (78)	1150 (22)
Pfizer-BioNTech only	22473 (58)	–	18129 (81)	4344 (19)	7741 (59)	–	5614 (73)	2127 (27)
Combination of mRNA products	357 (1)	–	77 (22)	280 (78)	115 (1)	–	16 (14)	99 (86)

Abbreviations: Col, column; ICU, intensive care unit; SMD, standardized mean or proportion difference; Unvacc., unvaccinated.

^a Immunocompromised status at hospitalizations was defined by the presence (presumed immunocompromised) or absence (presumed non-immunocompromised) of at least one discharge code from the International Classification of Diseases, 9th and 10th Revisions, for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.

^b Vaccination status was categorized based on number and type of vaccine dose(s) received before the hospitalization index date. Unvaccinated patients had not received any COVID-19 vaccine doses. Patients who had received two mRNA vaccine doses were included in the ‘2 doses’ category if their second dose was ≥ 14 days earlier. Patients who had received three mRNA vaccine doses were included in the ‘3 doses’ category if their third dose was ≥ 7 days earlier. Recipients of the Janssen vaccine were excluded from this table.

^c An absolute SMD ≥ 0.20 indicates a non-negligible difference in variable distributions between hospitalizations for vaccinated versus unvaccinated patients. The SMD was calculated as the average of the absolute value of the SMD for vaccinated with 2 doses versus unvaccinated and the absolute value of the SMD for vaccinated with 3 doses versus unvaccinated.

All SMDs are reported as the absolute SMD.

^d Other race includes Asian, Native Hawaiian, or other Pacific islander, American Indian or Alaska Native, other not listed, and multiple races.

^e Chronic respiratory condition at discharge was defined as the presence of discharge codes from the International Classification of Diseases, 9th and 10th Revisions, for asthma, chronic obstructive pulmonary disease, or other lung disease.

^f Among vaccinated patients

Table 3. mRNA COVID-19 vaccine effectiveness against laboratory-confirmed COVID-19–associated emergency department or urgent care events and hospitalizations among non-immunocompromised and immunocompromised adults, by number and timing of vaccine doses and vaccine product received, August–December 2021.

	Emergency department and urgent care events						Hospitalizations					
	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion n SARS-CoV-2 positive (row %)	Unadjusted VE ^a % (95% CI)	Adjusted VE ^b % (95% CI)	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted VE ^a % (95% CI)	Adjusted VE ^b % (95% CI)
Non-immunocompromised adults^c												
Unvaccinated (referent)	94113	60798 (38.6)	33315 (78.1)	35.4	–	–	32406	19132 (34.9)	13274 (82.5)	41.0	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	89546	80680 (51.2)	8866 (20.8)	9.9	80 (79-80)	81 (81-82)	31891	29227 (53.3)	2664 (16.6)	8.3	87 (86-87)	87 (86-87)
2 doses (14-149 days earlier)	23915	22383 (14.2)	1532 (3.6)	6.4	88 (87-88)	87 (86-88)	6415	6112 (11.2)	303 (1.9)	4.7	93 (92-94)	92 (91-93)
2 doses (≥150 days earlier)	65631	58297 (37.0)	7334 (17.2)	11.2	77 (76-78)	78 (78-79)	25476	23115 (42.2)	2361 (14.7)	9.3	85 (85-86)	85 (84-85)
3 doses (≥7 days earlier)	16412	15947 (10.1)	465 (1.1)	2.8	95 (94-95)	94 (93-94)	6585	6437 (11.7)	148 (0.9)	2.2	97 (96-97)	96 (95-97)
Moderna only												
2 doses (≥14 days earlier)	35236	32390 (20.5)	2846 (6.7)	8.1	84 (83-85)	86 (85-86)	13685	12753 (23.3)	932 (5.8)	6.8	89 (89-90)	90 (89-91)
2 doses (14-149 days earlier)	7810	7395 (4.7)	415 (1.0)	5.3	90 (89-91)	90 (89-91)	2335	2246 (4.1)	89 (0.6)	3.8	94 (93-95)	94 (92-95)
2 doses (≥150 days earlier)	27426	24995 (15.9)	2431 (5.7)	8.9	82 (81-83)	84 (83-85)	11350	10507 (19.2)	843 (5.2)	7.4	88 (88-89)	89 (88-90)
3 doses (≥7 days earlier)	4886	4768 (3.0)	118 (0.3)	2.4	95 (95-96)	95 (94-96)	1961	1921 (3.5)	40 (0.2)	2.0	97 (96-98)	96 (95-97)

Pfizer-BioNTech only												
2 doses (≥14 days earlier)	54121	48111 (30.6)	6010 (14.1)	11.1	77 (77-78)	77 (77-78)	18129	16399 (29.9)	1730 (10.8)	9.5	85 (84-86)	83 (82-84)
2 doses (14-149 days earlier)	16033	14917 (9.5)	1116 (2.6)	7.0	86 (85-870)	85 (84-86)	4047	3833 (7.0)	214 (1.3)	5.3	92 (91-93)	90 (88-91)
2 doses (≥150 days earlier)	38088	33194 (21.1)	4894 (11.5)	12.8	73 (72-74)	73 (72-74)	14082	12566 (22.9)	1516 (9.4)	10.8	83 (82-84)	80 (79-82)
3 doses (≥7 days earlier)	10615	10293 (6.5)	322 (0.8)	3.0	94 (94-95)	93 (92-94)	4344	4244 (7.7)	100 (0.6)	2.3	97 (96-97)	95 (94-96)
Immunocompromised adults^c												
Unvaccinated (referent)	3198	2514 (32.6)	684 (60.1)	21.4	–	–	5832	4574 (27.3)	1258 (60.5)	21.6	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	4223	3840 (49.8)	383 (33.7)	9.1	63 (58-68)	67 (62-72)	9635	8930 (53.3)	705 (33.9)	7.3	71 (68-74)	72 (69-75)
2 doses (14-149 days earlier)	871	810 (10.5)	61 (5.4)	7.0	72 (64-79)	72 (62-79)	1823	1717 (10.2)	106 (5.1)	5.8	78 (72-82)	75 (68-80)
2 doses (≥150 days earlier)	3352	3030 (39.3)	322 (28.3)	9.6	61 (55-66)	64 (57-69)	7812	7213 (43.0)	599 (28.8)	7.7	70 (66-73)	70 (66-73)
3 doses (≥7 days earlier)	1427	1356 (17.60)	71 (6.2)	5.0	81 (75-85)	73 (64-80)	3376	3258 (19.4)	118 (5.7)	3.5	87 (84-89)	81 (76-86)
Moderna only												
2 doses (≥14 days earlier)	1698	1557 (20.2)	141 (12.4)	8.3	67 (60-73)	69 (62-76)	4005	3748 (22.4)	257 (12.3)	6.4	75 (71-78)	76 (72-80)
2 doses (14-149 days earlier)	317	302 (3.9)	15 (1.3)	4.7	82 (69-89)	79 (64-88)	645	618 (3.7)	27 (1.3)	4.2	84 (77-89)	81 (69-88)
2 doses (≥150 days earlier)	1381	1255 (16.3)	126 (11.1)	9.1	63 (55-70)	64 (54-72)	3360	3130 (18.7)	230 (11.1)	6.8	73 (69-77)	73 (68-77)
3 doses (≥7 days earlier)	452	435 (5.6)	17 (1.5)	3.8	86 (77-91)	77 (58-87)	1150	1124 (6.7)	26 (1.2)	2.3	92 (88-94)	87 (79-92)
Pfizer-BioNTech only												
2 doses (≥14 days earlier)	2509	2268 (29.4)	241 (21.2)	9.6	61 (54-67)	61 (54-67)	5614	5166 (30.8)	448 (21.5)	8.0	68 (65-72)	66 (61-70)
2 doses (14-149 days earlier)	551	506 (6.6)	45 (4.0)	8.2	67 (55-76)	62 (45-73)	1175	1096 (6.5)	79 (3.8)	6.7	74 (67-79)	68 (58-75)

2 doses (≥ 150 days earlier)	1958	1762 (22.9)	196 (17.2)	10.0	59 (52-66)	56 (46-64)	4439	4070 (24.3)	369 (17.7)	8.3	67 (63-71)	64 (58-69)
3 doses (≥ 7 days earlier)	919	870 (11.3)	49 (4.3)	5.3	79 (72-85)	74 (62-82)	2127	2040 (12.2)	87 (4.2)	4.1	84 (81-88)	76 (69-82)

Abbreviations: CI, confidence interval; VE, vaccine effectiveness.

^a Unadjusted vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design.

^b Adjusted vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design and adjusted for age, geographic region, calendar time, prior positive SARS-CoV-2 test result, and local SARS-CoV-2 circulation on the day of each medical visit, and weighted for patients' inverse propensity to be vaccinated (if the patient was vaccinated) or unvaccinated (if the patient was not vaccinated). Generalized boosted regression trees were used to estimate the propensity to be vaccinated based on sociodemographic characteristics, underlying medical conditions, known prior SARS-CoV-2 infection, and facility or hospital characteristics.

^c Immunocompromised status was defined by the presence (presumed immunocompromised) or absence (presumed non-immunocompromised) of at least one discharge code from the International Classification of Diseases, 9th and 10th Revisions, for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.

Table 4. Relative effectiveness of three versus two doses of mRNA COVID-19 vaccines against laboratory-confirmed COVID-19–associated emergency department or urgent care events and hospitalizations among non-immunocompromised and immunocompromised adults, by vaccine product received, August–December 2021.

	Emergency department and urgent care events						Hospitalizations					
	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted Relative VE ^a % (95% CI)	Adjusted Relative VE ^b % (95% CI)	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted Relative VE ^a % (95% CI)	Adjusted Relative VE ^b % (95% CI)
Non-immunocompromised adults^c												
Any mRNA vaccine												
2 doses (≥14 days earlier) (referent)	89546	80680 (83.5)	8866 (95.0)	9.9	–	–	31891	29227 (82.0)	2664 (94.7)	8.3	–	–
3 doses (≥7 days earlier)	16412	15947 (16.5)	465 (5.0)	2.8	73 (71-76)	72 (68-75)	6585	6437 (18.0)	148 (5.3)	2.2	75 (70-79)	75 (68-80)
Moderna only												
2 doses (≥14 days earlier) (referent)	35236	32390 (87.2)	2846 (96.0)	8.1	–	–	13685	12753 (86.9)	932 (95.9)	6.8	–	–
3 doses (≥7 days earlier)	4886	4768 (12.8)	118 (4.0)	2.4	72 (66-77)	69 (60-76)	1961	1921 (13.1)	40 (4.1)	2.0	72 (61-79)	71 (57-81)
Pfizer-BioNTech only												
2 doses (≥14 days earlier) (referent)	54121	48111 (82.4)	6010 (94.9)	11.1	–	–	18129	16399 (79.4)	1730 (94.5)	9.5	–	–
3 doses (≥7 days earlier)	10615	10293 (17.6)	322 (5.1)	3.0	75 (72-78)	74 (70-78)	4344	4244 (20.6)	100 (5.5)	2.3	78 (73-82)	77 (70-83)
Immunocompromised adults^c												
Any mRNA vaccine												
2 doses (≥14 days earlier) (referent)	4223	3840 (73.9)	383 (84.4)	9.1	–	–	9635	8930 (73.3)	705 (85.7)	7.3	–	–

3 doses (≥ 7 days earlier)	1427	1356 (26.1)	71 (15.6)	5.0	48 (32-60)	44 (24-58)	3376	3258 (26.7)	118 (14.3)	3.5	54 (44-62)	48 (34-59)
Moderna only												
2 doses (≥ 14 days earlier) (referent)	1698	1557 (78.2)	141 (89.2)	8.3	–	–	4005	3748 (76.9)	257 (90.8)	6.4	–	–
3 doses (≥ 7 days earlier)	452	435 (21.8)	17 (10.8)	3.8	57 (28-74)	47 (3-71)	1150	1124 (23.1)	26 (9.2)	2.3	66 (49-78)	57 (33-73)
Pfizer-BioNTech only												
2 doses (≥ 14 days earlier) (referent)	2509	2268 (72.3)	241 (83.1)	9.6	–	–	5614	5166 (71.7)	448 (83.7)	8.0	–	–
3 doses (≥ 7 days earlier)	919	870 (27.7)	49 (16.9)	5.3	47 (27-61)	51 (29-66)	2127	2040 (28.3)	87 (16.3)	4.1	51 (38-61)	40 (21-55)

Abbreviations: CI, confidence interval; VE, vaccine effectiveness.

^a Unadjusted relative vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design.

^b Adjusted relative vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design and adjusted for age, geographic region, calendar time, prior positive SARS-CoV-2 test result, and local SARS-CoV-2 circulation on the day of each medical visit, and weighted for patients' inverse propensity to be three-dose vaccinated (if the patient was three-dose vaccinated) or two-dose vaccinated (if the patient was two-dose vaccinated). Generalized boosted regression trees were used to estimate the propensity to be three-dose vaccinated based on sociodemographic characteristics, underlying medical conditions, known prior SARS-CoV-2 infection, and facility or hospital characteristics.

^c Immunocompromised status was defined by the presence (presumed immunocompromised) or absence (presumed non-immunocompromised) of at least one discharge code from the International Classification of Diseases, 9th and 10th Revisions, for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.

Table 5. mRNA COVID-19 vaccine effectiveness against laboratory-confirmed COVID-19–associated emergency department or urgent care events and hospitalizations among subgroups of adults with specific types of immunocompromising conditions, by number of vaccine doses, August–December 2021.

	Emergency department or urgent care events						Hospitalizations					
	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted VE ^a % (95% CI)	Adjusted VE ^b % (95% CI)	Total	No. SARS-CoV-2 negative (col %)	No. SARS-CoV-2 positive (col %)	Proportion SARS-CoV-2 positive (row %)	Unadjusted VE ^a % (95% CI)	Adjusted VE ^b % (95% CI)
Solid malignancy only^c												
Unvaccinated (referent)	845	713 (29.7)	132 (68.4)	15.6	–	–	1639	1400 (25.1)	239 (61.4)	14.6	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	1282	1227 (51.1)	55 (28.5)	4.3	76 (66-83)	79 (69-85)	3148	3011 (54.0)	137 (35.2)	4.3	73 (67-79)	76 (69-82)
3 doses (≥7 days earlier)	465	459 (19.1)	6 (3.1)	1.3	93 (84-97)	87 (70-95)	1174	1161 (20.8)	13 (3.3)	1.1	93 (88-96)	92 (84-96)
Hematologic malignancy only^c												
Unvaccinated (referent)	190	148 (25.6)	42 (50.0)	22.1	–	–	361	286 (25.9)	75 (46.9)	20.8	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	351	318 (54.9)	33 (39.3)	9.4	63 (40-78)	82 (66-90)	678	608 (55.1)	70 (43.8)	10.3	56 (37-69)	73 (58-82)
3 doses (≥7 days earlier)	122	113 (19.5)	9 (10.7)	7.4	72 (40-87)	50 (-36-81)	225	210 (19.0)	15 (9.4)	6.7	73 (51-85)	72 (43-87)
Rheumatologic or inflammatory disorder only^c												
Unvaccinated (referent)	751	542 (33.4)	209 (63.9)	27.8	–	–	1101	787 (25.7)	314 (61.6)	28.5	–	–

Any mRNA vaccine												
2 doses (≥ 14 days earlier)	957	849 (52.3)	108 (33.0)	11.3	67 (57-74)	72 (63-80)	1931	1751 (57.2)	180 (35.3)	9.3	74 (68-79)	76 (70-81)
3 doses (≥ 7 days earlier)	242	232 (14.3)	10 (3.1)	4.1	89 (79-94)	84 (61-93)	541	525 (17.1)	16 (3.1)	3.0	92 (87-95)	89 (79-94)
Other intrinsic immune condition or immunodeficiency only^c												
Unvaccinated (referent)												
	838	641 (40.3)	197 (71.9)	23.5	–	–	1529	1154 (36.6)	375 (75.9)	24.5	–	–
Any mRNA vaccine												
2 doses (≥ 14 days earlier)	833	765 (48.1)	68 (24.8)	8.2	71 (61-78)	79 (70-85)	1751	1642 (52.1)	109 (22.1)	6.2	80 (74-84)	83 (77-87)
3 doses (≥ 7 days earlier)	193	184 (11.6)	9 (3.3)	4.7	84 (68-92)	82 (46-94)	364	354 (11.2)	10 (2.0)	2.8	91 (84-95)	89 (73-96)
Organ or stem cell transplant only^c												
Unvaccinated (referent)												
	115	94 (27.8)	21 (28.0)	18.3	–	–	143	100 (22.0)	43 (50.6)	30.1	–	–
Any mRNA vaccine												
2 doses (≥ 14 days earlier)	157	122 (36.1)	35 (46.7)	22.3	-28 (-135-30)	11 (-102-61)	254	222 (48.9)	32 (37.6)	12.6	66 (44-80)	73 (49-86)
3 doses (≥ 7 days earlier)	141	122 (36.1)	19 (25.3)	13.5	30 (-37-65)	59 (-24-86)	142	132 (29.1)	10 (11.8)	7.0	82 (63-92)	39 (-69-78)
Immunocompromised without organ or stem cell transplant^d												
Unvaccinated (referent)												
	2975	2333 (33.0)	642 (64.2)	21.6	–	–	5423	4265 (27.6)	1158 (62.3)	21.4	–	–
Any mRNA vaccine												
2 doses (≥ 14 days earlier)	3909	3590 (50.8)	319 (31.9)	8.2	68 (63-72)	72 (67-76)	8955	8335 (53.9)	620 (33.3)	6.9	73 (70-75)	74 (70-77)
3 doses (≥ 7 days earlier)	1187	1148 (16.2)	39 (3.9)	3.3	88 (83-91)	83 (75-89)	2960	2878 (18.6)	82 (4.4)	2.8	90 (87-92)	86 (81-90)

Moderna only												
2 doses (≥14 days earlier)	1587	1466 (20.7)	121 (12.1)	7.6	70 (63-76)	74 (67-80)	3737	3509 (22.7)	228 (12.3)	6.1	76 (72-79)	76 (72-80)
3 doses (≥7 days earlier)	379	370 (5.2)	9 (0.9)	2.4	91 (83-95)	83 (62-92)	985	968 (6.3)	17 (0.9)	1.7	94 (90-96)	91 (83-95)
Pfizer-BioNTech only												
2 doses (≥14 days earlier)	2307	2110 (29.8)	197 (19.7)	8.5	66 (60-71)	67 (60-73)	5203	4811 (31.1)	392 (21.1)	7.5	70 (66-73)	68 (63-72)
3 doses (≥7 days earlier)	763	736 (10.4)	27 (2.7)	3.5	87 (80-91)	86 (77-92)	1893	1831 (11.8)	62 (3.3)	3.3	88 (84-90)	83 (76-88)
Immunocompromised with organ or stem cell transplant^d												
Unvaccinated (referent)	223	181 (28.3)	42 (30.4)	18.8	–	–	409	309 (24.1)	100 (45.2)	24.4	–	–
Any mRNA vaccine												
2 doses (≥14 days earlier)	314	250 (39.1)	64 (46.4)	20.4	-10 (-70-29)	14 (-43-48)	680	595 (46.3)	85 (38.5)	12.5	56 (39-68)	59 (40-72)
3 doses (≥7 days earlier)	240	208 (32.6)	32 (23.2)	13.3	34 (-10-60)	56 (14-78)	416	380 (29.6)	36 (16.3)	8.6	71 (56-81)	62 (36-77)
Moderna only												
2 doses (≥14 days earlier)	111	91 (14.2)	20 (14.5)	18.0	5 (-71-48)	-6 (-113-48)	268	239 (18.6)	29 (13.1)	10.8	63 (41-76)	68 (46-81)
3 doses (≥7 days earlier)	73	65 (10.2)	8 (5.8)	11.0	47 (-19-760)	67 (12-88)	165	156 (12.1)	9 (4.1)	5.4	82 (64-91)	87 (67-95)
Pfizer-BioNTech only												
2 doses (≥14 days earlier)	202	158 (24.7)	44 (31.9)	21.8	-20 (-93-25)	-5 (-82-39)	411	355 (27.6)	56 (25.3)	13.6	51 (30-66)	37 (5-58)
3 doses (≥7 days earlier)	156	134 (21.0)	22 (15.9)	14.1	29 (-24-60)	58 (11-80)	234	209 (16.3)	25 (11.3)	10.7	63 (41-77)	47 (6-70)

Abbreviations: CI, confidence interval; VE, vaccine effectiveness.

^a Unadjusted vaccine effectiveness was calculated as [1–odds ratio] x 100%, estimated using a test-negative design.

^b Adjusted vaccine effectiveness was calculated as $[1 - \text{odds ratio}] \times 100\%$, estimated using a test-negative design and adjusted for age, geographic region, calendar time, prior positive SARS-CoV-2 test result, and local SARS-CoV-2 circulation on the day of each medical visit, and weighted for patients' inverse propensity to be vaccinated (if the patient was vaccinated) or unvaccinated (if the patient was not vaccinated). Generalized boosted regression trees were used to estimate the propensity to be vaccinated based on sociodemographic characteristics, underlying medical conditions, known prior SARS-CoV-2 infection, and facility or hospital characteristics.

^c Five immunocompromising conditions were defined by the presence of a discharge code from the International Classification of Diseases, 9th and 10th Revisions, for 1) solid malignancy, 2) hematologic malignancy, 3) rheumatologic or inflammatory disorder, 4) other intrinsic immune condition or immunodeficiency, or 5) organ or stem cell transplant. Patients with more than one of these types of immunocompromising conditions were excluded from these analyses restricted to persons with only one type of condition.

^d Receipt of an organ or stem cell transplant was defined by the presence of a discharge code from the International Classification of Diseases, 9th and 10th Revisions, for organ or stem cell transplant. Immunocompromised adults without an organ or stem cell transplant had a discharge code for at least one other immunocompromising condition: 1) solid malignancy, 2) hematologic malignancy, 3) rheumatologic or inflammatory disorder, or 4) other intrinsic immune condition or immunodeficiency. In contrast to the subgroup for 'Organ or stem cell transplant only', immunocompromised adults with an organ or stem cell transplant were included even if they had at least one additional type of immunocompromising condition.